Why the study?
Does PCI with everolimus eluting stents compared to CABG improve mid-term adverse cardiovascular outcomes in patients with coronary artery disease?
Does PCI with everolimus eluting stents compared to CABG improve mid-term adverse cardiovascular outcomes in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
In patients with coronary artery disease, PCI with everolimus-eluting stents yields similar mid-term mortality to CABG, but is associated with higher rates of myocardial infarction, MACE, and repeat revascularization.
This study aimed to compare the mid-term adverse cardiovascular outcomes associated with Coronary Artery Bypass Surgery (CABG) and Percutaneous Coronary Intervention (PCI) with Everolimus Eluting Stents (EES). Electronic databases were searched for studies comparing the mid-term (>1 year) adverse cardiovascular outcomes between CABG and PCI with EES. Odd Ratios (OR) with 95% Confidence Intervals (CIs) were calculated and the pooled analyses were performed with RevMan 5.3 software. A total number of 5207 patients were involved in this analysis. No significant difference was observed in mortality between CABG and EES with OR: 0.90, 95% CI: 0.73-1.10; P = 0.30. Moreover, CABG was associated with a high stroke rate, with OR: 0.73, 95% CI: 0.45-1.17; P = 0.19, without any statistical significant. CABG was associated with significantly lower Major Adverse Cardiac Events and Myocardial Infarction with OR: 1.46, 95% CI: 1.05-2.04; P = 0.03 and OR: 1.46, 95% CI: 1.01-2.12; P = 0.05 respectively whereas PCI was associated with a significantly higher repeated revascularization with OR: 2.21; 95% CI: 1.76-2.77; P = 0.00001. In conclusion, significant differences were noted in several subgroups analyzing the mid-term cardiovascular outcomes between CABG and EES.
No takes yet. Share an insight, caveat, or question.
Bundhun et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: